|
Press Releases |
|
 |
|
Friday, July 25, 2025 |
|
雲頂新耀宣布配售股份 擬集資約15.725億港元 |
雲頂新耀有限公司(HKEX1952.HK)是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司,今日宣布以先舊後新配售22,561,000股,集資約15.725億港元,發行股份數占現有股本約6.87%, 占經擴大後的總股數約6.43%。 more info >> |
|
云顶新耀宣布配售股份 拟集资约15.725亿港元 |
云顶新耀有限公司(HKEX1952.HK)是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,今日宣布以先旧后新配售22,561,000股,集资约15.725亿港元,发行股份数占现有股本约6.87%, 占经扩大后的总股数约6.43%。 more info >> |
|
Tuesday, July 15, 2025 |
|
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力 |
今日雲頂新耀(01952.HK)股價表現亮眼,盤中最高價觸及73.4港元,再創新高。 more info >> |
|
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力 |
今日云顶新耀(01952.HK)股价表现亮眼,盘中最高价触及73.4港元,再创新高。 more info >> |
|
Friday, July 4, 2025 |
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
雲頂新耀發佈AI+mRNA平台新突破 重塑中國mRNA國際競爭格局 |
近期,雲頂新耀(HKEX: 1952.HK)在上海成功舉辦「2025雲頂新耀mRNA創新技術平台研發日」,系統展示其自主構建的AI+mRNA平台的最新進展,以及多個管線項目在腫瘤及自身免疫疾病治療中的前沿突破。 more info >> |
|
云顶新耀发布AI+mRNA平台新突破 重塑中国mRNA国际竞争格局 |
近期,云顶新耀(HKEX: 1952.HK)在上海成功举办“2025云顶新耀mRNA创新技术平台研发日”,系统展示其自主构建的AI+mRNA平台的最新进展,以及多个管线项目在肿瘤及自身免疫疾病治疗中的前沿突破。 more info >> |
|
Thursday, July 3, 2025 |
|
雲頂新耀公佈EVER001-1b/2a期階段性數據 專家看好其作為新一代BTK療法的潛力 |
7月1日,雲頂新耀(HKEX: 1952.HK)公佈其自主研發的共價可逆BTK抑制劑EVER001在治療原發性膜性腎病(pMN)的1b/2a期臨床研究中取得最新數據。 more info >> |
|
云顶新耀公布EVER001-1b/2a期阶段性数据 专家看好其作为新一代BTK疗法的潜力 |
7月1日,云顶新耀(HKEX: 1952.HK)公布其自主研发的共价可逆BTK抑制剂EVER001在治疗原发性膜性肾病(pMN)的1b/2a期临床研究中取得最新数据。 more info >> |
|
Friday, June 20, 2025 |
|
雲頂新耀加速全球佈局 耐賦康(R)與EVER001雙引擎釋放創新藥價值潛力 |
近日,天風證券舉辦「雲頂新耀(1952.HK)耐賦康®&EVER001——2025歐洲腎臟協會(ERA)大會數據解讀會」,圍繞公司在ERA大會披露的最新研究成果,深入分析其在慢病治療領域的產品潛力、國際化合作前景及平台型創新價值。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
潼關黃金獲納入MSCI全球小型股指數 資本市場影響力進一步提升
Aug 13, 2025 19:19 HKT/SGT
|
|
|
Intellifusion Submits an Application to List on the Hong Kong Stock Exchange: A National Breakthrough in AI Inference Chips
Aug 13, 2025 18:33 HKT/SGT
|
|
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 15:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 15:05 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 14:53 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 14:18 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 14:15 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 13, 2025 14:13 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 12:00 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 11:00 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 10:15 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸運觀眾現場觀賽 深度參與世界人形機器人運動會
Aug 13, 2025 09:58 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸运观众现场观赛 深度参与世界人形机器人运动会
Aug 13, 2025 09:43 HKT/SGT
|
|
|
康基醫療收到由董事長鍾鳴、TPG及卡塔爾投資局(QIA)牽頭財團提出之私有化要約 助力公司實現長遠願景
Aug 13, 2025 09:27 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|